{
    "Trade/Device Name(s)": [
        "BIOEASY Multi-Drug Test Cup"
    ],
    "Submitter Information": "Shenzhen Bioeasy Biotechnology Co., Ltd.",
    "510(k) Number": "K193480",
    "Predicate Device Reference 510(k) Number(s)": [
        "K182530"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL",
        "NGI",
        "NFW",
        "NFY",
        "NGG",
        "NFT",
        "NFV",
        "PTH",
        "NGM",
        "PTG",
        "QAW",
        "QBF"
    ],
    "Summary Letter Date": "December 11, 2019",
    "Summary Letter Received Date": "December 16, 2019",
    "Submission Date": "January 27, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3100",
        "21 CFR 862.3870",
        "21 CFR 862.3250",
        "21 CFR 862.3610",
        "21 CFR 862.3640",
        "21 CFR 862.3170",
        "21 CFR 862.3650",
        "21 CFR 862.3150",
        "21 CFR 862.3620",
        "21 CFR 862.3910",
        "21 CFR 862.3700"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System",
        "Cannabinoids Test System",
        "Cocaine and Cocaine Metabolites Test System",
        "Methamphetamine Test System",
        "Morphine Test System",
        "Benzodiazepine Test System",
        "Opiate Test System",
        "Barbiturate Test System",
        "Methadone Test System",
        "Tricyclic Antidepressant Drugs Test System",
        "Propoxyphene Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Oxazepam",
        "Cocaine",
        "Marijuana",
        "Methamphetamine",
        "Morphine",
        "Oxycodone",
        "Secobarbital",
        "Buprenorphine",
        "Methylenedioxy-methamphetamine",
        "Phencyclidine",
        "Methadone",
        "Nortriptyline",
        "d-Propoxyphene"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [
        "Urine cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay"
    ],
    "Methodologies": [
        "Immunochemistry"
    ],
    "Submission Type(s)": [
        "Test",
        "Kit",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for BIOEASY Multi-Drug Test Cup qualitative multi-analyte urine drug test using lateral flow immunochromatographic assay technology.",
    "Indications for Use Summary": "Qualitative and simultaneous detection of drugs of abuse (amphetamine, oxazepam, cocaine, marijuana, methamphetamine, morphine, oxycodone, secobarbital, buprenorphine, methylenedioxy-methamphetamine, phencyclidine, methadone, nortriptyline, and d-propoxyphene) in human urine at defined cutoff concentrations; for in vitro diagnostic use only.",
    "fda_folder": "Toxicology"
}